4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies

Amenorrhea Evaluation: Primary & Secondary Etiologies

Amenorrhea—the absence of menses—signals an endocrine, genetic, or anatomic disruption within the hypothalamic-pituitary-ovarian (HPO) axis or reproductive tract. Normal menarche occurs at a mean age of 12.4 years in the United States, preceded by an orderly pubertal cascade: thelarche (breast budding, Tanner 2, stimulated by ovarian estradiol), adrenarche/pubarche (adrenal androgenic pubic/axillary hair), peak height velocity (linear somatic growth), and menarche (typically 2 to 2.5 years after thelarche).

---

Clinical Definitions

• Primary Amenorrhea:
  1. Absence of menses by age 15 in an individual with normal growth and secondary sexual characteristics.
  2. Absence of menses by age 13 in an individual who lacks secondary sexual characteristics (delayed puberty / hypogonadism).
• Secondary Amenorrhea:
  1. Absence of menses for >=3 consecutive months in an individual with previously regular menstrual cycles.
  2. Absence of menses for >=6 consecutive months in an individual with a history of irregular oligomenorrhea.

---

Stepwise Primary Amenorrhea Diagnostic Algorithm

The evaluation of primary amenorrhea begins with two initial determinations: breast development (clinical bioassay of systemic estrogen exposure) and pelvic ultrasound (confirming the presence or absence of the uterus and cervix).

                                  Primary Amenorrhea
                                          │
                      ┌───────────────────┴───────────────────┐
               Breasts Present                         Breasts Absent
               (Estrogen +)                            (Estrogen -)
                      │                                       │
         ┌────────────┴────────────┐             ┌────────────┴────────────┐
   Uterus Present           Uterus Absent  Uterus Present           Uterus Absent
         │                         │             │                         │
Outflow Obstruction:      Differentiate:   Measure Gonadotropins:  Rare 46,XY steroid
• Imperforate hymen       • MRKH (46,XX)   • High FSH: Turner      biosynthesis defects
• Transverse septum       • CAIS (46,XY)     (45,X; ovarian dys.)  (17-alpha-hydroxylase)
                                           • Low/NL FSH: Kallmann,
                                             FHA, CNS lesions

1. Breasts Present, Uterus Present (Estrogen +, Uterus +)

Reflects an intact HPO axis and functional ovaries producing physiologic estradiol, with normal Müllerian organogenesis. The underlying pathology is an anatomic outflow tract obstruction:

• Imperforate Hymen: Failure of the inferior vaginal plate to canalize. Adolescents present with cyclic pelvic pain, amenorrhea, urinary retention, and a bulging, bluish membrane at the introitus (hematocolpos). Managed with surgical hymenotomy.
• Transverse Vaginal Septum: Failure of vertical fusion between Müllerian ducts and the urogenital sinus. Patients present with cyclic pain and hematometra, but examination reveals a blind vaginal pouch without an introital bulge. Evaluated by pelvic MRI and treated with surgical resection.

2. Breasts Absent, Uterus Present (Estrogen -, Uterus +)

Reflects failure of pubertal ovarian estrogen production, with intact Müllerian structures due to absence of anti-Müllerian hormone (AMH). Measure serum FSH and LH:

• Hypergonadotropic Hypogonadism (Elevated FSH >30–40 mIU/mL, low estradiol): Primary gonadal failure / ovarian dysgenesis. Loss of follicular negative feedback causes elevated gonadotropins.
  • Turner Syndrome (45,X or mosaicism): The most common genetic cause (~50% of hypergonadotropic cases). Accelerated fetal atresia leaves fibrous "streak gonads." Features include short stature, webbed neck, shield chest, high-arched palate, and cardiac defects (coarctation of the aorta, bicuspid aortic valve). Karyotyping is mandatory. Management includes growth hormone and pubertal hormone replacement therapy.
  • Swyer Syndrome (46,XY pure gonadal dysgenesis): Phenotypic females with streak gonads and a uterus. Carries a 20%–30% risk of malignant germ cell tumors (gonadoblastoma, dysgerminoma); mandates prompt bilateral prophylactic gonadectomy.
• Hypogonadotropic Hypogonadism (Low or normal FSH/LH, low estradiol): Central failure of GnRH or gonadotropins.
  • Kallmann Syndrome: Defective embryonic migration of GnRH neurons and olfactory axons. Classic triad: primary amenorrhea, absent puberty, and anosmia or hyposmia.
  • Functional Hypothalamic Amenorrhea (FHA): Chronic severe energy deficiency, extreme athletic training, or eating disorders in early adolescence.
  • Pituitary/Hypothalamic Tumors: Craniopharyngioma or prolactinoma. Requires contrast-enhanced brain MRI.

3. Breasts Present, Uterus Absent (Estrogen +, Uterus -)

Differentiate Müllerian Agenesis (MRKH) from Complete Androgen Insensitivity Syndrome (CAIS):

4. Breasts Absent, Uterus Absent (Estrogen -, Uterus -)

Extremely rare 46,XY steroidogenesis defects (e.g., 17-alpha-hydroxylase deficiency, 17,20-lyase deficiency) where testes produced AMH (regressing Müllerian ducts) but failed to produce androgens or estrogens.

---

Secondary Amenorrhea Stepwise Diagnostic Cascade

Follow a structured 4-step sequence:

Step 1: Initial Essential Laboratory Evaluation

• hCG: Exclude pregnancy.
• TSH: Identify hypothyroidism (which elevates TRH, raising prolactin and disrupting GnRH) or hyperthyroidism.
• Prolactin: Elevated prolactin suppresses GnRH. Review dopamine-blocking medications. If persistently elevated, obtain pituitary MRI.

Step 2: Progestin Withdrawal Challenge

Administer oral medroxyprogesterone acetate (MPA) 10 mg daily for 10 to 14 days:

• Positive Withdrawal Bleed (bleeding within 2–7 days post-progestin): Confirms adequate endogenous estrogen priming the endometrium and a patent outflow tract. Diagnosis: Anovulation / Ovulatory Dysfunction (e.g., PCOS). Prescribe cyclical progestins, combined contraceptives, or LNG-IUS for endometrial protection.
• Negative Withdrawal Bleed (no bleeding): Indicates anatomical disruption OR profound hypoestrogenism. Proceed to Step 3.

Step 3: Combined Estrogen-Progestin Challenge

Administer oral conjugated equine estrogens (CEE) 1.25–2.5 mg daily (or oral estradiol 2 mg daily) for 21 days, adding MPA 10 mg daily for the final 10 days:

• Negative Challenge (No bleeding): Endometrium is unreactive or blocked -> Asherman Syndrome (intrauterine synechiae) or severe cervical stenosis. Typically follows vigorous sharp curettage during pregnancy or postpartum. Confirmed by hysteroscopy or saline infusion sonohysterography.
• Positive Challenge (Withdrawal bleeding occurs): Endometrium and outflow tract are intact. Amenorrhea is due to hypoestrogenism. Proceed to Step 4.

Step 4: Gonadotropin Differentiation (FSH and LH)

• Hypergonadotropic Hypogonadism (FSH >25 IU/L): Primary Ovarian Insufficiency (POI) in women <40 years. The 2024 ESHRE/ASRM guideline requires only one elevated FSH with at least 4 months of disordered cycles; repeat in 4–6 weeks only if the diagnosis is uncertain. Evaluate for autoimmune oophoritis (21-hydroxylase antibodies), Fragile X (FMR1 premutation), and karyotype anomalies.
• Hypogonadotropic Hypogonadism (Low or normal FSH <5–10 mIU/mL, low LH):
  • Functional Hypothalamic Amenorrhea (FHA): Relative Energy Deficiency in Sport (RED-S), low energy availability, disordered eating, or severe psychological stress suppressing hypothalamic kisspeptin and GnRH.
  • Sheehan Syndrome: Postpartum pituitary ischemic necrosis from massive obstetric hemorrhage; presents with failure to lactate (agalactorrhea) and amenorrhea.

---

Long-Term Health Consequences & Management

Profound hypoestrogenism in POI and chronic FHA accelerates bone resorption, causing early osteopenia and osteoporosis. It also promotes endothelial dysfunction and adverse lipid profiles.

• Hormone Replacement Therapy (HRT): Physiological hormone replacement (transdermal estradiol 100 mcg patch daily + oral micronized progesterone 200 mg nightly 12–14 days/month) is mandatory until the median age of natural menopause (age 51).
• Bone Support: DEXA scan, elemental calcium (1,200 mg daily), and vitamin D3 (800–1,000 IU daily).